In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.

Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...

UCB SA has a promising drug, Bimzelx, despite temporary EBITDA decline and potential regulatory hurdles ahead. Learn more ...

Oral Opportunity in PsO (US) 2024, highlights a shifting landscape in the treatment for moderate-to-severe PsO. As emerging oral therapies gain traction, the study underscores their potential to ...

Steroids, hyaluronic acid injections, and regenerative therapies, such as PRP and stem cell injections, are among the ...